Lannett Company, Inc. (NYSE:

) today announced that it has commenced shipping of its Morphine Sulfate Oral Solution product. The company received approval from the U.S. Food and Drug Administration for its 505(b)(2) New Drug Application (NDA) on June 23, 2011. Sales of Morphine Sulfate Oral Solution for the last 12 months at Average Wholesale Price were approximately $31.7 million, according to Wolters Kluwer.